Effects of Encapsulated Propolis on Blood Glycemic Control, Lipid Metabolism, and Insulin Resistance in Type 2 Diabetes Mellitus Rats

Table 1

Effects of encapsulated propolis on FBG in T2DM rats (𝑥  ± S.D.).

Group	Dosage	𝑛	Fasting blood glucose (mmol/L)
	(administration)		0 week	2 week	4 week	6 week	8 week	10 week
Normal control	1 mL/100 g; distilled water (p.o.)	12	6.07±0.31 **	6.18±0.21 **	6.09±0.28 **	6.09±0.24 **	6.13±0.24 **	6.19±0.33 **
Model control	1 mL/100 g; distilled water (p.o.)	12	7.35±0.69	7.39±0.46	7.51±0.76	8.23±0.84	8.61±0.73	9.05±1.06
Low-dose EP	50 mg/kg encapsulated; propolis (p.o.)	12	7.30±0.77	7.82±0.52	7.67±0.69	7.13±0.52 **	7.74±0.49 **	7.88±0.46 **
Middle-dose EP	100 mg/kg encapsulated; propolis (p.o.)	12	7.20±1.73	7.79±0.70	7.68±0.64	7.51±0.50 **	7.59±0.40 **	7.51±0.50 **
High-dose EP	200 mg/kg encapsulated; propolis (p.o.)	12	7.17±1.20	7.68±0.84	7.63±0.85	7.67±0.41	7.32±0.60 **	7.37±0.68 **
Positive control	10 mg/kg; Pioglitazone HCL (p.o.)	12	7.28±1.45	7.68±0.72	6.93±0.64	7.01±0.47 **	7.53±0.45 **	7.54±0.46 **

Tukey post-hoc tests: *𝑃<.05 and **𝑃<.01 compared with model control group.